AKTX vs. BFRI, GRTX, ADIL, MTEM, LGVN, HEPA, AEZS, ATHE, MBRX, and VIRI
Should you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Biofrontera (BFRI), Galera Therapeutics (GRTX), Adial Pharmaceuticals (ADIL), Molecular Templates (MTEM), Longeveron (LGVN), Hepion Pharmaceuticals (HEPA), Aeterna Zentaris (AEZS), Alterity Therapeutics (ATHE), Moleculin Biotech (MBRX), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical preparations" industry.
Biofrontera (NASDAQ:BFRI) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.
Akari Therapeutics received 256 more outperform votes than Biofrontera when rated by MarketBeat users. However, 60.00% of users gave Biofrontera an outperform vote while only 54.93% of users gave Akari Therapeutics an outperform vote.
Biofrontera presently has a consensus price target of $18.00, suggesting a potential upside of 984.34%. Given Akari Therapeutics' higher probable upside, research analysts clearly believe Biofrontera is more favorable than Akari Therapeutics.
10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 0.2% of Biofrontera shares are owned by insiders. Comparatively, 61.8% of Akari Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Biofrontera has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.
Akari Therapeutics has a net margin of 0.00% compared to Akari Therapeutics' net margin of -59.09%. Biofrontera's return on equity of 0.00% beat Akari Therapeutics' return on equity.
Akari Therapeutics has lower revenue, but higher earnings than Biofrontera.
In the previous week, Akari Therapeutics had 1 more articles in the media than Biofrontera. MarketBeat recorded 1 mentions for Akari Therapeutics and 0 mentions for Biofrontera. Akari Therapeutics' average media sentiment score of 0.00 equaled Biofrontera'saverage media sentiment score.
Summary
Akari Therapeutics beats Biofrontera on 8 of the 13 factors compared between the two stocks.
Get Akari Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akari Therapeutics Competitors List
Related Companies and Tools
